USD
+$0.00
(+0.00%
)At Close (As of Nov 5, 2025)
$55.33M
Market Cap
-
P/E Ratio
-1.64
EPS
$2.41
52 Week High
$0.59
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $71K |
| Total Revenue | $1.9M |
| Cost Of Revenue | $1.8M |
| Costof Goods And Services Sold | $1.8M |
| Operating Income | -$74M |
| Selling General And Administrative | $19M |
| Research And Development | $56M |
| Operating Expenses | $74M |
| Investment Income Net | - |
| Net Interest Income | $2M |
| Interest Income | $6.7M |
| Interest Expense | $4.7M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $1.8M |
| Income Before Tax | -$71M |
| Income Tax Expense | - |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$71M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$66M |
| Ebitda | -$64M |
| Net Income | -$71M |
| Field | Value (USD) |
|---|---|
| Total Assets | $127M |
| Total Current Assets | $113M |
| Cash And Cash Equivalents At Carrying Value | $111M |
| Cash And Short Term Investments | $111M |
| Inventory | - |
| Current Net Receivables | - |
| Total Non Current Assets | $14M |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | - |
| Intangible Assets Excluding Goodwill | - |
| Goodwill | - |
| Investments | - |
| Long Term Investments | - |
| Short Term Investments | - |
| Other Current Assets | $2.1M |
| Other Non Current Assets | - |
| Total Liabilities | $54M |
| Total Current Liabilities | $15M |
| Current Accounts Payable | $3M |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $1.6M |
| Total Non Current Liabilities | $38M |
| Capital Lease Obligations | $11M |
| Long Term Debt | $26M |
| Current Long Term Debt | - |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $37M |
| Other Current Liabilities | $11M |
| Other Non Current Liabilities | - |
| Total Shareholder Equity | $73M |
| Treasury Stock | - |
| Retained Earnings | -$415M |
| Common Stock | $5K |
| Common Stock Shares Outstanding | $44M |
| Field | Value (USD) |
|---|---|
| Operating Cashflow | -$56M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $1.8M |
| Capital Expenditures | $254K |
| Change In Receivables | - |
| Change In Inventory | - |
| Profit Loss | - |
| Cashflow From Investment | -$254K |
| Cashflow From Financing | $13M |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | - |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | -$71M |
| Field | Value (USD) |
|---|---|
| Gross Profit | $71K |
| Total Revenue | $1.9M |
| Cost Of Revenue | $1.8M |
| Costof Goods And Services Sold | $1.8M |
| Operating Income | -$74M |
| Selling General And Administrative | $19M |
| Research And Development | $56M |
| Operating Expenses | $74M |
| Investment Income Net | - |
| Net Interest Income | $2M |
| Interest Income | $6.7M |
| Interest Expense | $4.7M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $1.8M |
| Income Before Tax | -$71M |
| Income Tax Expense | - |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$71M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$66M |
| Ebitda | -$64M |
| Net Income | -$71M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Werewolf Therapeutics, Inc. (HOWL) is an innovative biopharmaceutical company focused on developing next-generation immune-based therapies for cancer treatment. Headquartered in Cambridge, Massachusetts, the company utilizes its proprietary platform to engineer novel therapeutics that enhance the body’s immune response against tumors. With a robust pipeline of product candidates targeting a range of oncology indications, Werewolf Therapeutics is well-positioned to advance its mission of improving patient outcomes through cutting-edge science and precision medicine.